Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) is now available.
Nanjing Leads Biolabs Co., Ltd. has entered into an exclusive global license agreement with Dianthus Therapeutics, Inc. to advance LBL-047, a novel anti-BDCA2-TACI bispecific fusion protein aimed at treating autoimmune diseases. This partnership allows Dianthus to develop and commercialize LBL-047 outside Greater China, while Nanjing Leads Biolabs will receive significant upfront and milestone payments, potentially enhancing its financial standing and reinforcing its commitment to innovative drug development.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. operates in the biotechnology industry, focusing on the development of innovative drug candidates for autoimmune diseases. The company is committed to advancing treatments that address severe autoimmune conditions, leveraging partnerships to enhance its market presence.
Average Trading Volume: 1,723,948
See more data about 9887 stock on TipRanks’ Stock Analysis page.